Panion Animal Health AB develops an innovative gene therapy treatment for epilepsy in dogs. The development product CG01-canine has just entered the clinical phase with an ongoing dog study in USA.
This study will explore the efficacy of the product in drug-refractory epilepsy cases in privately owned dogs and it builds on two earlier dogs studies conducted with healthy animals to show the safety of the product. The safety studies showed a very good safety profile of the product and provide a good basis to trust that the future product authorization will not be hindered by adverse events occurring after treatment.
The ongoing study will give the first evidence of the level of treatment effect, which so far has been deducted from multiple rat studies. The announcing of the clinical efficacy study is progressing well with information to dog owners and referring vets in the New York area, and the first dog screenings have been scheduled. The training of personnel and technics are ongoing, and the product itself is manufactured in accordance with the time plan. The first study data are expected by the end of 2019.
To investigate Panion’s future connections and options in the Animal Health field, Lars Thunberg, the chairman of the board, presented Panion at the Animal Health Investment Forum in London, 26-27 February.
He reports: “It was a fantastic show with all the big companies in the Animal Health branch.
Panion represented the new thinking in the pet show regarding transforming human medical science in to animal health. I met a lot of different potential partners, everything was focusing on the future treatment about pet care.
Panion was one of four companies who was chosen to give a slideshow about the development. I think Panion did well. We understand that the thinking of building up expert know-how about the different rules between US (FDA) an EU (EMA) is very important.
Panion is unique in its development which is a Phase 2 study going on. There were some talks about partnering and licensing, which will be followed up during this year. We will think about it and try to understand the possibilities.
When Panion have finished the ongoing study there are several options for out-licensing the product to companies who have the distribution. Overall, I am very content with the responses and opportunities that were coming to light during the event.”